Iughetti, L. https://orcid.org/0000-0003-0370-7872
Antoniazzi, F.
Giavoli, C.
Bona, G.
Aversa, T.
Greggio, N. A.
Guazzarotti, L.
Minelli, R.
Perrone, L.
Persani, L.
Pozzobon, G.
Ragusa, L.
Stagi, S.
Tornese, G.
Zecchino, C.
Gallinari, P.
Zouater, H.
Fedeli, P.
Zucchini, S.
Article History
Received: 9 October 2019
Accepted: 8 June 2020
First Online: 15 June 2020
Compliance with ethical standards
:
: LI has participated in Advisory Boards for Eli Lilly, Italy and Novo Nordisk, Italy; FA has received honoraria from Eli Lilly, Novo Nordisk and Ipsen and research funding from Merck Serono; CG, TA, NAG, LG, RM, L Perrone, LR, SS, and GT have no conflict of interest to declare; L Persani has been an invited speaker for Sandoz and Merck-Serono, and has received unconditional research funds from Novartis, IBSA and Merck-Serono; GB has received honoraria from Ferring, Novo, Serono, Lilly, Sandoz; CZ has received honoraria from Sandoz, Novo, Medtronic; HZ is an employee of Sandoz Biopharmaceutical c/o HEXAL AG, Germany; PG and PF are employees of Sandoz S.p.A, Milan, Italy; SZ has been a member of expert committees for Eli Lilly Diabetes, Italy, and Roche Diagnostics.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Comitato Etico Indipendente dell’Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, n°120/2007/O/Oss) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from the parents or legal guardians of all individual participants included in the study.